We regularly advise on merger filings in China, including transactions involving significant competition issues. We have assisted clients in obtaining clearance in complex cases, including by developing and negotiating remedies where required. We also advise stakeholders in transactions that raise competition concerns.

Our team also supports multi-jurisdictional filings, working closely with counsel in other major jurisdictions and, where appropriate, coordinating global merger control strategy. In addition, we advise on gun-jumping risks and investigations relating to transactions implemented without prior notification.

Selected experience

• JX Metal / Tatsuta, acting as Monitor Trustee
• Simcere / Tobishi, advising Simcere
• Qualcomm / Autotalks, advising Qualcomm
• SK hynix / Intel NAND business, advised SK Hynix
• NVIDIA / ARM, advised stakeholders
• Broadcom Corporation / BROCADE, advised stakeholders
• Didi / Uber China, advised Didi

We have one of the most experienced antitrust litigation teams in China, with substantial experience in both antitrust civil litigation and administrative litigation. Our team has acted in a number of landmark competition disputes before Chinese courts, including cases that clarified important issues relating to market dominance, resale price maintenance and the arbitrability of antitrust claims. 

Selected experience

• Qihoo 360 v. Tencent (the “3Q” case) - successfully defended the client in the first antitrust case heard by the Supreme People’s Court (the “SPC”). This case was selected as “Guiding Case No.78” in China.
• JD.com v. Alibaba - represented JD.com in its abuse of dominance litigation concerning alleged “either-or” arrangements, with a record-breaking claim amount in antitrust litigation in China.
• Qualcomm v. Apple - represented Qualcomm in litigations related to alleged abuse of dominant position and FRAND licensing terms.
• Yangtze Pharma v. HIPI Pharma - successfully appealed against an unfavorable first-instance judgment and obtained a full victory before the SPC. This case was selected into “Top Ten Typical Antitrust and Anti-Unfair Competition Cases of People’s Court in 2023” and “Recent Typical Antitrust Cases” by the SPC.
• The first judicial review case on RPM decision in China -successfully defended an antitrust enforcement agency before the SPC. This case resolved the long-standing divergent approaches taken by antitrust authorities and courts.
• The first judicial review case on merger review decision in China - successfully defended SAMR’s decision.
• The first hub-and-spoke case in China – successfully appealed an unfavorable first-instance judgment and obtained a full victory before the SPC. This case was selected as a “Typical Antitrust Case” by the SPC and as one of “100 Cases in Five Years” by the IP tribunal of the SPC.
• The first abuse of administrative power case heard by the SPC - successfully challenged local government’s abuses of administrative power before the SPC. This case was selected as one of the “Five Typical Antitrust Cases” by the SPC in 2025.
• The first case where the SPC determined antitrust litigation was non-arbitrable - represented the client in proceedings that led to a SPC ruling that antitrust disputes are not subject to arbitration.

We regularly represent clients in responding to antitrust investigations and regulatory inquiries by Chinese competition authorities. Our team closely tracks enforcement priorities and regulatory developments, enabling us to provide practical and commercially realistic advice in sensitive matters.

Selected experience

• Qualcomm Case
• Alibaba Case
• The first antitrust investigation against patent pool
• Multiple SEP-related cases - represented a number of SEP holders in responding to regulatory investigations or inquiries.
• DRAM Case - represented a Korean manufacturer in responding to an antitrust investigation by SAMR.
• Multiple global cartel cases - including matters involving auto parts, RoRo shipping, automotive, and etc.
• represented several major internet platforms in antitrust investigations and regulatory inquiries.
• represented a number of multinational pharmaceutical/medical device companies in responding to antitrust investigations and market surveys.

As foreign investments are increasingly subject to China's National Security Review (NSR) system, we also provide NSR risk assessment, negotiation, and reporting services to foreign clients.

• Assisted a well-known international enterprise in its NSR application for the acquisition of a Chinese grain and oil company

• Represented a well-known international enterprise in its NSR negotiation for the acquisition of a Chinese port enterprise

• Represented a well-known international enterprise in its NSR negotiation for the acquisition of a Chinese high-tech enterprise

• Provided NSR-related consultation and risk assessment services for a foreign-invested greenfield investment project